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STEM CELL TOURISM:
THE CHALLENGE AND PROMISE OF INTERNATIONAL REGULATION OF
EMBRYONIC STEM CELL-BASED THERAPIES
Lesley N. DeRenzo
Most cells in the human body are committed to fulfilling a single
function. In contrast, embryonic stem cells have the ability to become over
200 distinct cell types. Because of this distinctive characteristic, embryonic
stem cells hold vast promise to treat a variety of diseases and disorders.
Nevertheless, scientific experts concede that substantial advances in basic
biology and clinical technique are essential before embryonic stem cells are
readily available for clinical use. Despite the lack of safety and efficacy
testing in humans, there are clinics around the world charging patients
thousands of dollars for embryonic stem cell-based therapy. As a result,
scientists have reported instances of patients suffering adverse outcomes
after receiving unregulated stem cell-based therapies. Recognizing the
global nature of science and medicine, this Note explores various solutions
the United Nations can take to regulate the use of embryonic stem cells in
clinical practice.
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I. INTRODUCTION
Stem cell-based therapies have existed since 1968 when clinicians
performed the first bone marrow transplantation.1 Thirty years later, Dr.
James A. Thomson, Director of Regenerative Biology for the Morgridge
Institute for Research, derived the first human embryonic stem cell (hESC)
1
Fritz H. Bach et al., Bone-Marrow Transplantation in a Patient with the Wiskott-Aldrich
Syndrome, 2 THE LANCET 1364 (1968) (discussing a bone marrow transplant to replace abnormal cells with healthy cells capable of making normal platelets, T cells, and B cells); see
also Robert A. Good et al., Immunological Reconstitution of Sex-Linked Lymphopenic Immunological Deficiency, 2 THE LANCET 1366 (1968) (discussing a bone marrow transplant
procedure for an individual with combined T-cell and B-cell immunodeficiency). A bone
marrow transplant delivers healthy bone marrow stem cells into a patient and replaces bone
marrow that is either not working properly or has been destroyed (i.e., ablated) by chemotherapy or radiation. See U.S. Nat‘l Library of Med., Bone Marrow Transplantation,
MEDLINEPLUS, http://www.nlm.nih.gov/medlineplus/bonemarrowtransplantation.html (last
updated Mar. 28, 2011).
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lines2 from left-over, pre-implantation human embryos (donated to biomedical research).3 Dr. Thomson theorized that his findings could revolutionize
medicine by generating unlimited sources of human cells for transplantation
therapies.4 However, he cautioned that ―substantial advances in basic developmental biology‖ were essential before hESC-based therapies would be
ready for clinical applications.5 Indeed, scientific experts maintain that the
only established, stem cell-based treatment in clinical practice is bone marrow transplantation, which incorporates the use of hematopoietic stem
cells.6

2

Human embryonic stem cells [hESCs] are: (1) derived from human embryos, (2) can
self-replicate indefinitely, and (3) can develop into cells and tissues of the three primary
germ layers (i.e., endoderm, mesoderm, and ectoderm). See infra Appendix B & D; see also
James A. Thomson et al., Embryonic Stem Cell Lines Derived from Human Blastocysts, 282
SCI. 1145, 1145 (1998) (discussing the generation of cardiomyocytes from the first human
embryonic stem cell lines derived from blastocysts). Furthermore, a hESC line is a population of cells isolated from cryopreserved, pre-implantation human embryos (usually four- or
five-days old) that can be grown indefinitely in vitro. See DEP‘T OF HEALTH AND HUMAN
SERVICES, NAT‘L INSTITUTES OF HEALTH, STEM CELLS: SCIENTIFIC PROGRESS AND FUTURE
RESEARCH DIRECTIONS 13 (2001), available at http://stemcells.nih.gov/staticresources/info/
scireport/PDFs/fullrptstem.pdf; see also infra Appendix D.
3
Thomson et al., supra note 2, at 1145. Individuals that had undergone in vitro fertilization [IVF] and no longer needed their left-over embryos donated their embryos for use in Dr.
Thomson‘s study. Id. ―[IVF] is the joining of a[n] . . . egg and . . . sperm in a [petri] dish.‖
U.S. Nat‘l Library of Med., In Vitro Fertilization (IVF), MEDLINEPLUS,
http://www.nlm.nih.gov/medlineplus/ency/article/007279.htm (last updated Jan. 25, 2011)
(stating that ―[i]n vitro means ‗outside the body[,]‘ [and] [f]ertilization means the sperm has
attached to and entered the egg.‖).
4
Thomson et al., supra note 2, at 1146–47.
5
Id. at 1147 (emphasis added).
6
Bone marrow transplantations are used primarily to treat diseases of the blood system
(e.g., treatment for leukemia and similar blood-related cancers). See, e.g., George Daley et
al., Mapping the Road to the Clinical Translation of Stem Cells, 2 CELL STEM CELL 139, 139
(2008). Hematopoietic (i.e., blood-forming) stem cells are extracted from bone marrow and
are used to replace blood cells destroyed from high doses of chemotherapy. See, e.g., Jos
Domen et al., Bone Marrow (Hematopoietic) Stem Cells, in U.S. DEP‘T OF HEALTH AND
HUMAN SERVICES, REGENERATIVE MEDICINE 22 (2006), available at http://stemcells.nih.gov/
staticresources/info/scireport/PDFs/Regenerative_Medicine_2006.pdf. Hematopoietic stem
cells are different from embryonic stem cells. More specifically, embryonic stem cells can
develop into nearly every type of cell in the body, whereas hematopoietic stem cells divide to
form more blood-forming stem cells, or can mature into one of three types of blood cells
(i.e., white blood cells, which fight infection; red blood cells, which carry oxygen; and platelets, which help the blood to clot). See generally U.S. DEP‘T OF HEALTH AND HUMAN
SERVICES, STEM CELL BASICS (2009), available at http://stemcells.nih.gov/staticresources/
info/basics/SCprimer2009.pdf (a comprehensive review on the state of the science on stem
cell research).
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Once human cellular-based and tissue-based products7 became
available for therapeutic applications, Congress assigned regulatory responsibility of these products to the U.S. Food and Drug Administration (FDA). 8
The FDA identifies a broad spectrum of safety concerns related to hESCbased products for use in human transplantation.9 More specifically, the
FDA asserts that hESCs—and their derivatives—pose the risk for: (i) spontaneous formation of tumors after injection of hESCs into a human subject;
(ii) migration of hESCs to a different site in the human body than what was
originally intended; and (iii) development of immunogenicity because of the
body‘s reaction to the foreign material expressed from the human proteins
on the hESC product.10
Moreover, it is essential that all left-over, pre-implantation embryos
donated for clinical applications are screened for infectious diseases.11 Accordingly, without standardized safety screening of hESCs for infectious
diseases, hESC-based therapies pose the risk of transmitting infectious diseases such as Hepatitis B and HIV/AIDS to the recipients.12 While hESC
research has many safety challenges, the FDA states that the goal of facili7

FDA regulations define cellular-based and tissue-based products as ―articles containing
or consisting of human cells or tissues that are intended for implantation, transplantation,
infusion, or transfer into a human recipient.‖ 21 C.F.R. § 1271.3(d) (2010).
8
See generally 21 C.F.R. § 1271 (2010) (outlining FDA‘s good tissue practice requirements).
Of FDA‘s many responsibilities for human health and security, the FDA is responsible for
assuring the safety, efficacy, and security of biological products. What Does FDA Do?, FOOD
& DRUG ADMIN., http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194877.htm (last
updated Dec. 17, 2010).
9
Donald W. Fink Jr., FDA Regulation of Stem Cell-Based Products, 324 SCI. 1662
(2009) (presenting how the FDA ensures subjects enrolled in clinical studies involving stem
cell-based products are not exposed to significant and unreasonable risk due to the FDA‘s
review of medical and scientific information to determine whether there is sufficient safety
assurance to permit initiation of human clinical studies); see also Dina Gould Halme & David A. Kessler, FDA Regulation of Stem-Cell-Based Therapies, 355 NEW ENG. J. MED. 1730
(2006) (articulating how the FDA‘s promulgated regulations regarding human cells, tissues,
and cellular-based and tissue-based products, provide an appropriate regulatory structure for
the wide range of stem cell-based products that may be developed to replace or repair damaged tissue).
10
Fink Jr., supra note 9, at 1662; see also Stem Cell Science: The Foundation of Future
Cures: Before the Subcomm. on Health, U.S. House of Representatives’ Comm. on Energy
and Commerce, 110th Cong. (2008) (statement of Dr. Elias A. Zerhouni, Dir. of the Nat‘l
Institutes of Health, U.S. Dep‘t of Health and Human Services).
11
See 21 C.F.R. §§ 1270.21, 1271.75(a)(1)(i)–(v), 1271.85(a)(1)–(5) (2010).
12
In the United States, any human tissue intended for transplantation must be tested for
the following communicable viruses: (1) HIV, (2) Hepatitis B, and (3) Hepatitis C. 21 C.F.R.
§ 1270.21(a)(1)–(4) (2010); see also discussion infra Part III(A) (discussing threats posed by
the potential use of modern molecular technology to produce biological weapons and the use
of stem cells as a critical link to both evade and produce such weapons).
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tating the development of safe and effective hESC-based products is attainable.13 And, the FDA emphasizes that cooperative, interdisciplinary efforts
are essential to ensure patient safety.14
Despite well-documented safety risks, there are clinics throughout
the world, and outside of the FDA‘s jurisdiction, offering unregulated
hESC-based therapies.15 Unregulated clinics increase the probability that
vulnerable patient populations receiving these treatments will experience
adverse outcomes.16 The risks of patients suffering harm from unsubstantiated hESC-based treatments are mitigated within the United States, and in
other developed countries, because Federal agencies actively regulate
against unsafe medical practices.17 Unfortunately, at this time, there is no
international governing body authorized to set and enforce regulations on
the use of hESCs in medical practice.18 Thus, the burden of regulating
hESC-based therapies is dependent on the enforcement mechanisms of individual countries.19
As stem cell treatments emerge as a developing area of medical
tourism, scientific experts are becoming increasingly concerned with the
potential adverse impacts of hESC-based treatments offered without regulatory oversight.20 Because of this concern, the International Society for Stem
13

Fink Jr., supra note 9, at 1663.
Id.
15
Daley et al., supra note 6, at 139.
16
See id.
17
Sorapap Kiatpongsan & Douglas Sipp, Commentary, Offshore Stem Cell Treatments,
NATURE REP. STEM CELLS (Dec. 3, 2008), http://www.nature.com/stemcells/2008/0812/0812
03/full/stemcells.2008.151.html (analyzing how the market approach to experimental medicine, in which doctors and entrepreneurs exploit patient trust and take advantage of the
dearth of cell therapy regulations in many countries, is destined to end badly unless there are
clear and enforceable rules to regulate such behavior).
18
Id.
19
Id.
20
Medical tourism is defined as travel with the aim of improving one‘s health. See MILICA
Z. BOOKMAN & KARLA R. BOOKMAN, MEDICAL TOURISM IN DEVELOPING COUNTRIES 1
(2007); see also Eliza Barclay, Stem-Cell Experts Raise Concerns About Medical Tourism,
373 THE LANCET 883 (2009) (investigating how stem cell therapies are emerging as a
growing area of medical tourism, even while research is still in its early stages); Olle
Lindvall & Insoo Hyun, Medical Innovation Versus Stem Cell Tourism, 324 SCI. 1664 (2009)
(―Stem cell tourism is criticized on grounds of consumer fraud, blatant lack of scientific
justification, and patient safety‖ and the ―conditions under which ‗unproven‘ therapies may
be offered to patients outside of regular clinical trials‖). The World Health Organization
[WHO] identifies medical tourism as trending upward. BOOKMAN & BOOKMAN, supra note
20, at 2 (citing David Woodward et al., Globalization, Global Public Goods and Health, in
WHO, TRADE IN HEALTH SERVICES: GLOBAL, REGIONAL AND COUNTRY PERSPECTIVES 3, 7
(2002). Further, a 2008 survey of health care consumers found that the frequency of patients
traveling abroad to obtain health care is increasing. DELOITTE CENTER FOR HEALTH
SOLUTIONS, DELOITTE, 2008 SURVEY OF HEALTH CARE CONSUMERS (2008), available at
14
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Cell Research (ISSCR) issued guidelines targeting ―stem cell tourism.‖21
The ISSCR‘s guidelines highlight the need for well-designed clinical trials
as an essential element for administering any proposed hESC-based ―therapy.‖22 While the ISSCR acknowledges a place for investigator-led medical
innovation, it does so with the caveat that such interventions must be conducted in line with the ethical obligation to do no harm.23
Although the guidelines advocate for an international framework,
they carry no legal force.24 Moreover, despite the efforts of a wellintentioned international professional society, the guidelines are easily ignored by unregulated clinics.25
Therefore, Part II of this Note examines the promise of hESC-based
therapies and highlights the challenges, or potential dangers, of stem cell
tourism without an international regulatory framework. Part III explores a
range of effective solutions to combat administering unsafe hESC-based
therapies. Specifically, this includes the analysis and application of: (i) a
binding U.N. Security Council (Security Council) Resolution to effectuate
immediate action in the interest of national security and public health; (ii) a
http://www.deloitte.com/assets/DcomUnitedStates/Local%20Assets/Documents/us_chs_Con
sumerSurveyExecutiveSummary_200208.pdf (highlighting that patients traveling to a new
location for the purpose of obtaining quality health care at a lower price is becoming more
prevalent and will likely continue as an emerging trend in accessing health care).
21
See INT‘L SOC‘Y FOR STEM CELL RES. [ISSCR], Guidelines for the Clinical Translation
of Stem Cells (2008), available at http://www.isscr.org/clinical_trans/pdfs/ISSCRGL
ClinicalTrans.pdf (presenting the international guidelines defining scientific, clinical, regulatory, ethical, and societal issues that must be addressed to ensure that basic stem cell research
is responsibly transitioned into appropriate clinical applications for treating patients). ISSCR
is ―an independent, nonprofit organization established to promote and foster the exchange
and dissemination of information and ideas relating to stem cells, to encourage the general
field of research involving stem cells and to promote professional and public education in all
areas of stem cell research and application.‖ Mission Statement, ISSCR, http://www.isscr.org
/mission/index.htm (last updated Oct. 2, 2003). ISSCR members agree to abide by the
ISSCR‘s professional standards when conducting human embryonic stem cell research. Join
ISSCR, ISSCR, http://www.isscr.org/membership/index.htm (last updated Nov. 16, 2010).
22
Guidelines for the Clinical Translation of Stem Cells, supra note 21. ―[C]linical trials. . .
are generally considered to be biomedical or health-related research studies in human beings
that follow a pre-defined protocol.‖ Understanding Clinical Trials, CLINICALTRIALS.GOV,
http://clinicaltrials.gov/ct2/info/understand (last updated Sept. 20, 2007).
23
Kiatpongsan & Sipp, supra note 17.
24
Id.
25
See id. The most notorious example of clinicians and physicians disregarding medical
guidelines in relation to human subjects research is demonstrated by the heinous acts carried
out by Nazi doctors during World War II despite German regulations prohibiting such conduct. See, e.g., Michael A. Grodin, Historical Origins of the Nuremburg Code, in THE NAZI
DOCTORS AND THE NUREMBERG CODE: HUMAN RIGHTS IN HUMAN EXPERIMENTATION 121,
130–31 (George J. Annas & Michael A. Grodin eds., 1992) (citing 11 ReichsGesundheitsblatt 174–75 (1931)).
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resolution outside of the purview of biomedical regulations in which the
World Health Organization (WHO) could issue a non-binding resolution;
and (iii) model treaties and the codification of key portions of the ISSCR
guidelines into the form of a draft treaty.
II. HESC THERAPIES—INSPIRED BY THE PROMISE, RESPECTFUL OF THE
CHALLENGE, YET NAVIGATING WITHOUT A REGULATORY ROAD MAP
Human embryonic stem cells hold vast potential to treat a variety of
diseases and disorders.26 However, scientific experts concede that substantial advances in basic biology and clinical technique are critical before
hESCs are readily available for use in clinical applications.27 Despite the
lack of safety and efficacy testing in humans, there are clinics around the
world charging patients thousands of dollars for embryonic stem cell-based
therapy.28
As a result, patients lured by the promise of novel stem cell treatment have suffered adverse outcomes from unregulated therapies.29 Many
stem cell scientists agree that there is a need for systemic international regulation and oversight of hESC-based therapeutic treatments offered at various
clinics around the world.30

26
See infra Appendix C for an illustration of the potential of stem cell-based research; see
also discussion infra Part II(A) (discussing the promise of hESC-based research to allow for
an understanding of human development and cell specialization, thereby maximizing the
likelihood for the development of new therapies and treatments for human disease).
27
Stephen Pincock, Warning Against Stem Cell Tourism, ABC SCI. ONLINE (June 22,
2007), http://www.abc.net.au/science/news/stories/2007/1958206.htm (discussing the potentially grave risks of traveling internationally in search of untested stem cell treatments); see
also discussion infra Part II(A) (highlighting that there are several major hurdles to overcome before hESCs are available for clinical application, including: (1) generating large and
defined populations of the desired hESCs, (2) promoting the survival of grafted hESCderived cells after implantation, and (3) avoiding the formation of tumors or vigorous immune reactions caused by hESC-based therapy).
28
Online Briefing & Rapid Roundup: New Concern over Stem Cell Tourism, AUSTL. SCI.
MEDIA CTR. (Oct. 17, 2008), http://www.aussmc.org/2008/10/rapid-roundup-new-concernover-stem-cell-tourism-experts-respond/ (forum where experts discuss the danger of administering unproven hESC treatments to human subjects).
29
See, e.g., Norra MacReady, The Murky Ethics of Stem-Cell Tourism, 10 THE LANCET
ONCOLOGY 317 (2009) (highlighting recent cases of adverse outcomes from unproven stem
cell treatments).
30
See Guidelines for the Clinical Translation of Stem Cells, supra note 21.
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The Challenge and Promise of hESC-Based Therapies

Over the past several years, scientists have made significant discoveries regarding the curative potential of hESCs.31 For example, in 2009,
scientists demonstrated in mice that hESC-derived natural killer cells32 were
better at destroying blood cancer and solid tumors (e.g., breast and prostate
cancer) than natural killer cells derived from umbilical cord blood.33 This
finding could promote the use of hESC-derived natural killer cells in humans for cancer therapy.34
Studies in mice have also shown the possibility of engineering cardiovascular tissue for transplantation in humans by inducing hESCs to become heart cells.35 If successful in humans, this therapy could replace damaged heart tissue caused by heart disease.36 Another study successfully
demonstrated that hESC-derived neurons had the capability of repairing
damage caused by a stroke in rats.37 Rats that suffered mobility restrictions
with their paws were able to use their paws again normally after transplanta-

31

See infra Appendix C for an illustration of the potential of hESC-based research.
A natural killer cell is ―[a] type of immune cell that has granules (small particles) with
enzymes that can kill tumor cells or cells infected with a virus.‖ Definition of Natural Killer
Cell, NAT‘L CANCER INST., http://nci.nih.gov/dictionary/?CdrID=44062 (last visited Mar. 30,
2011).
33
Peter S. Woll et al., Human Embryonic Stem Cells Differentiate into a Homogeneous
Population of Natural Killer Cells with Potent In Vivo Antitumor Activity, 113 BLOOD 6094
(2009) (articulating that hESC-derived natural killer cells were better than umbilical cordderived natural killer cells at destroying cancer in a research study with mice).
34
Id.
35
Lei Yang et al., Human Cardiovascular Progenitor Cells Develop From a KDR+ Embryonic-Stem-Cell-Derived Population, 453 NATURE 524 (2008) (highlighting how scientists
verified that cardiomyocytes (i.e., heart cells) derived from embryonic stem cells expressed
cardiac genes, conducted electrical currents, and had the ability to repair the pumping ability
of mouse hearts damaged by induced heart attacks).
36
Id.
37
Marcel M. Daadi et al., Adherent Self-Renewable Human Embryonic Stem Cell-Derived
Neural Stem Cell Line: Functional Engraftment in Experimental Stroke Model, 3 PLOS ONE
1 (2008) (discussing that post-mortem tissue sections of treated rats‘ brains showed transplanted human neurons, derived from embryonic stem cells, grew towards the site of neuron
loss and did not appear to generate any tumors over a two month observational period).
Moreover, a ―[s]troke is the third leading cause of death in the U.S. and a leading cause of
serious, long-term disability in adults. A stroke . . . occurs when blood flow to the brain is
interrupted [causing] brain cells in the immediate area . . . to die because they [lack] the
oxygen and nutrients they need to function.‖ Know Stroke. Know the Signs. Act in Time.,
NAT‘L INST. OF NEUROLOGICAL DISORDERS & STROKE, http://www.ninds.nih.gov/disorders/
stroke/knowstroke.htm (last updated May 21, 2010).
32
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tion of the hESC-derived human neurons.38 Scientists hope to one day use
this treatment in humans who suffer mobility impairments from stroke.39
Scientists also successfully improved the motor functions of rats
with Parkinson‘s disease by injecting the rats with hESC-derived dopaminergic nerve cells.40 Unfortunately, the rats developed brain cancer as a result of stem cell treatment.41 However, if scientists can learn to control the
spontaneous cell differentiation that caused the brain cancer in the rats,
hESCs may one day be a plausible source of dopaminergic nerve cells for
humans suffering from Parkinson‘s disease.42
While hESC studies demonstrate promising advancements for potential therapies,43 they are not without significant scientific hurdles and
potential risks.44 For example, several studies have shown that hESC-based
38

Daadi et al., supra note 37.
See Guidelines for the Clinical Translation of Stem Cells, supra note 21.
40
Neeta S. Roy et al., Functional Engraftment of Human ES Cell-Derived Dopaminergic
Neurons Enriched by Coculture with Telomerase-Immortalized Midbrain Astrocytes, 12
NATURE MED. 1259 (2006) (articulating how a more efficient technique to derive dopaminergic neurons from hESCs allowed for the neurons to engraft into the brains of parkinsonian
rats and significantly improve motor function). Additionally, ―[p]arkinson‘s disease . . .
result[s] [in the] loss of dopamine-producing brain cells . . . [and] . . . [t]he four primary
symptoms . . . are tremor . . .; rigidity . . . of the limbs and trunk; . . . slowness of movement;
and postural instability . . . and coordination.‖ Parkinson’s Disease Information Page, NAT‘L
INST. OF NEUROLOGICAL DISORDERS & STROKE, http://www.ninds.nih.gov/disorders/
parkinsons_disease/parkinsons_disease.htm (last updated Mar. 30, 2011).
41
Roy et al., supra note 40, at 1259.
42
Id.
43
See, e.g., Testimony of the Director of the National Institutes of Health, Dr. Elias A.
Zerhouni, supra note 10; Gordon Keller, Embryonic Stem Cell Differentiation: Emergence of
a New Era in Biology and Medicine, 19 GENES DEV. 1129 (2005) (articulating that hESCs
have great potential for clinical applications to replace damaged cells and tissues in humans);
Gretchen Vogel, Ready or Not? Human ES Cells Head Toward the Clinic, 308 SCI. 1534
(2005) (discussing how dopamine-producing neurons derived from hESCs could provide an
unlimited and well characterized source of cells for a variety of treatments in humans);
Xianmin Zeng et al., An In Vitro Model of Human Dopaminergic Neurons Derived from
Embryonic Stem Cells: MPP+ Toxicity and GDNF Neuroprotection, 31
NEUROPSYCHOPHARMACOLOGY 2708 (2006) (discussing how ―the availability of human
dopaminergic neurons, derived from hESCs, allows for the possibility of directly examining
the unique features of human dopaminergic neurons with respect to their responses to pharmacological agents as well as to environmental and chemical toxins‖); Hannes Hentz et al.,
Cell Therapy and the Safety of Embryonic Stem Cell-Derived Grafts, 25 TRENDS BIOTECH. 24
(2006) (identifying that hESCs, or their derivatives, have an unprecedented potential to cure
degenerative disorders); Yang et al., supra note 35; and Daadi et al., supra note 37.
44
See, e.g., Deepa M. Deshpande et al., Recovery From Paralysis in Adult Rats Using
Embryonic Stem Cells, 60 ANNALS OF NEUROLOGY 32 (2006) (noting that while the hESCs
mediated partial recovery from paralysis, hESCs have not been tested in large animals or
humans and it is unclear whether hESCs will act the same way in a human host); Marcel
Dihné et al., Embryonic Stem Cell-Derived Neuronally Committed Precursor Cells with
Reduced Teratoma Formation After Transplantation into the Lesioned Adult Mouse Brain,
39
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therapies can: (i) cause cancer in the host subject through spontaneous differentiation; (ii) induce immunogenicity responses in the host subject because
of foreign human proteins expressed from the hESCs; and (iii) migrate to
different areas of the body other than the intended injection site.45
According to the National Institutes of Health (NIH),46 before scientists can use hESCs in transplantation therapy, hESCs must: (i) proliferate
extensively and generate sufficient quantities of specialized cells; (ii) differentiate into the desired cell type(s); (iii) survive in the recipient after transplant; (iv) integrate into the surrounding tissue after transplantation; (v)
function appropriately for extended periods of time; and (vi) avoid harming
the recipient.47
One company is on the path to demonstrate that hESC-based therapy in humans can be safe and efficacious. On January 23, 2009, the FDA
granted approval for the first study of hESC-based therapy in humans pursuant to a 21,000-page application submitted by Geron Corporation.48 Ge-

24 STEM CELLS 1458 (2006) (illustrating that more than 70 percent of mice that received
murine ESC-derived neural precursor cells develop tumors from the treatment); Rutger-Jan
Swijnenburg et al., Clinical Hurdles for the Transplantation of Cardiomyocytes Derived
from Human Embryonic Stem Cells: Role of Molecular Imaging, 18 CURRENT OP. IN
BIOTECH. 38 (2006) (indicating how there remain significant hurdles before safe and successful translation of hESC-based treatments will be available for clinical therapy, including the
need to assess cells following transplantation); Jia-Yi Li et al., Critical Issues of Clinical
Human Embryonic Stem Cell Therapy for Brain Repair, 31 TRENDS IN NEUROSCI. 146 (2008)
(highlighting that there are several major hurdles to overcome before hESCs are available for
clinical application, including: (1) generating large and defined populations of the desired
hESCs, (2) promoting the survival of grafted hESC-derived cells after implantation, and (3)
avoiding the formation of tumors or vigorous immune reactions caused by hESC-based therapy); Bin Lu et al., Long-Term Safety and Function of RPE from Human Embryonic Stem
Cells in Preclinical Models of Macular Degeneration, 27 STEM CELLS 2126 (2009) (reiterating that assessments of safety and efficacy are crucial before human hESC-based therapies
can move into the clinic); Hannes Hentze et al., Teratoma Formation by Human Embryonic
Stem Cells: Evaluation of Essential Parameters for Future Safety Studies, 2 STEM CELL
RES.198 (2009) (discussing that because transplantation of hESCs into immune-deficient
mice will result in uncontrolled cell-differentiation, standard techniques for the administration of hESC-derived cells are crucial to establishing the use of hESCs in therapeutic applications in humans); and Roy et al., supra note 40.
45
See sources cited supra note 44.
46
The National Institutes of Health [NIH] is the primary Federal agency responsible for
conducting and supporting medical research and supports over 300,000 extramural scientists
and research personnel at more than 3,000 institutions nationwide. About NIH, NIH,
http://www.nih.gov/about/index.html (last updated Oct. 27, 2010).
47
Testimony of the Director of the National Institutes of Health, Dr. Elias A. Zerhouni,
supra note 10, at 2 (emphasis added); see also sources cited supra note 44.
48
Geron Receives FDA Clearance to Begin World’s First Human Clinical Trial of Embryonic Stem Cell-Based Therapy, GERON CORP. (Jan. 23, 2009), http://www.geron.com/
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ron‘s application described twenty-four separate animal studies that demonstrated the effective and safe use of hESC-derived treatments for spinal cord
injuries in mice and rats.49 According to Geron, the animal studies provided
data showing that after the mice and rats received hESC-derived injections,
they regained the ability to use their hind legs and did not develop tumors
from the treatment.50 In vitro studies further demonstrated that the animals‘
immune systems did not attack Geron‘s hESC-derived cells as a foreign
tissue, minimizing the risk of immunogenicity.51
Despite the initial approval by the FDA, the project was placed on a
clinical hold in August 2009 based on the FDA‘s review of a non-clinical,
animal study.52 The animal study of concern to the FDA demonstrated that a
high frequency of animals injected with Geron‘s hESC-based product developed cysts in the injury site.53 In an effort to persuade the FDA to lift its
clinical hold, investigators recently completed a confirmatory, preclinical
study in rats to address the FDA‘s safety and efficacy concerns.54 The FDA
told Geron it would review the study‘s results and make a determination as
to whether Geron‘s proposed Phase I clinical trial55 can move forward.56 On
July 30, 2010, the FDA lifted its clinical hold on Geron‘s proposed Phase I

media/pressview.aspx?id=1148. Geron is a biopharmaceutical company based in California
and endeavors to develop first-class treatments for cancer and chronic degenerative diseases,
including spinal cord injury, heart failure and diabetes. See id.
49
Id.
50
Id.
51
Id.
52
Geron’s IND for Spinal Cord Injury Put on Hold, GERON CORP. (Aug. 18, 2009),
http://www.geron.com/media/pressview.aspx?id=1187 (discussing FDA‘s decision to place a
clinical hold on Geron‘s proposed clinical trial). A clinical hold is an order issued by the
FDA to delay a proposed clinical investigation or to suspend an ongoing investigation for the
development of a new drug or biological product. 21 C.F.R. § 312.42(a)(2010).
53
Geron and FDA Reach Agreement on Clinical Hold, GERON CORP. (Oct. 30, 2009),
http://www.geron.com/media/pressview.aspx?style=print&id=1195 (discussing Geron‘s
agreement with FDA to submit additional safety and efficacy animal studies regarding their
hESC-based product for spinal cord injuries).
54
Jason Sharp et al, Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor
Cell Transplants Improve Recovery after Cervical Spinal Cord Injury, 28 STEM CELLS 152
(2010) (discussing the ability of GRNOPC1, a proprietary hESC-derived population containing myelinating oligodendrocyte progenitor cells, to restore mobility to rats with cervical
spinal cord injuries).
55
Phase I studies ―evaluate how a new treatment should be given, how often, and what
dose is safe [and] usually enrolls only a small number of patients.‖ What is a Clinical Trial?,
NAT‘L CANCER INST., http://www.cancer.gov/clinicaltrials/learning/what-is-a-clinical-trial
(last updated Apr. 8, 2008).
56
See Geron and FDA Reach Agreement on Clinical Hold, supra note 53.
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clinical trial.57 And, in October 2010, Geron enrolled its first patient to test
the safety and efficacy of its proposed therapeutic application for spinal
cord injuries.58
Unfortunately, not all countries have stringent regulations on par
with that of the FDA to ensure the safety and efficacy of investigational,
new therapies.59 Moreover, these deficiencies are exposed and expanded as
individuals travel from a country with an effective regulatory regime to a
country without effective governance, regulation, and safety practices—
hopeful to find a novel treatment not available in their own country.
B.

Stem Cell Tourism

Many stem cell scientists agree that there is a need for systemic international regulation and oversight of hESC-based therapeutic treatments
offered at various clinics around the world.60 The act of individuals traveling to another country in the hope of finding a stem cell-based therapy is
known as ―stem cell tourism.‖61 Stem cell tourism has received intense scrutiny based on numerous reports of charlatanry, unsubstantiated claims in
advertisements, and adverse medical outcomes.62
Direct-to-consumer advertising via the internet is playing a significant role in attracting patients to seek stem cell therapies that turn out to be
unsubstantiated.63 Privately operated clinics around the world advertise,
57

Geron to Proceed with First Human Clinical Trial of Embryonic Stem Cell-Based Therapy, GERON CORP. (July 30, 2009), http://www.geron.com/media/pressview.aspx?id=1229.
58
Jodi Xu, Geron Enrolls First Patient in Stem-Cell Treatment Study, WALL ST. J. (Oct.
11, 2010, 3:33 P.M. EST), http://online.wsj.com/article/SB100014240527487037941045755
46371842991324.html.
59
Mark H. Wholey & Jordan D. Haller, An Introduction to the Food and Drug Administration and How it Evaluates New Devices: Establishing Safety and Efficacy, 18
CARDIOVASCULAR & INTERVENTIONAL RADIOLOGY 72 (1995) (discussing how FDA may
need to compromise some of its stringent approval standards to avoid industry‘s migration to
countries where the regulatory standards are less rigid).
60
Barclay, supra note 20 at 883–84; see also Bryn Nelson, Stem Cell Researchers Face
Down Stem Cell Tourism, NATURE REPORTS STEM CELLS (June 5, 2008), http://www.nature.
com/stemcells/2008/0806/080605/full/stemcells.2008.89.html (analyzing ―stem cell
tourism.‖ where people travel thousands of miles and pay thousands of dollars to receive
unregulated care); Kiatpongsan & Sipp, supra note 17; MacReady, supra note 29.
61
See Kiatpongsan & Sipp, supra note 17.
62
See id.
63
Darren Lau et al., Stem Cell Clinics Online: The Direct-to-Consumer Portrayal of Stem
Cell Medicine, 3 CELL STEM CELL 591 (2008) (describing that despite the immature state of
stem cell medicine, patients are seeking and accessing putative stem cell therapies in an
―early market.‖). The researchers analyzed stem cell clinic websites and found that ―the
portrayal of stem cell medicine on provider websites is optimistic and unsubstantiated by
peer-reviewed literature.‖ Id. For an example of a clinic offering unsubstantiated stem cell
therapies visit EmCell.com. EmCell.com is a website that makes contrary scientific claims
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without citing to any substantiated peer-reviewed literature backing their
practices, novel hESC-based therapies for many diseases in which conventional medicine is unavailable.64 The cost of stem cell therapy averages
$21,500 per treatment, excluding travel and accommodation.65 News reports
from 2009 indicate that clinics in China are charging as much as $69,420
per treatment.66
Furthermore, there is potential for serious side effects after receiving unregulated stem cell treatments.67 For example, in an observational
study in China, fetal brain tissue was transplanted into the lesions of more
than 400 patients with spinal cord injury at Beijing‘s Chaoyang and West
Hills (Xishan) hospitals.68 The visiting researchers could not find evidence
of clinical improvement in any of the patients they observed and reported
that several of the patients who received the treatment had developed meningitis from the stem cell injections.69
In another adverse outcome report, Israeli researchers from Sheba
Medical Center in Tel Aviv detailed the first case of a brain tumor that developed in a male child due to an unregulated stem cell transplantation therapy.70 The child and his family had sought unconventional stem cell therapy
that certain stem cells can migrate to an individual‘s damaged site, engraft, proliferate, undergo specialization under regulation of a new host, and substitute lost or damaged cells, thus
restoring the impaired body functions. For additional evidence of unsubstantiated stem cell
treatment claims, visit StemCellsChina.com. StemCellChina.com is a website providing
specious patient testimonials about stem cell treatments. Contrary to claims by EmCell and
StemCellsChina, the FDA asserts that hESCs—and their derivatives—pose the risk for (1)
spontaneous formation of tumors after injection of hESCs into a human subject; (2) migration of hESCs to a different site in the human body than what was originally intended; and
(3) development of immunogenicity because of the body‘s reaction to the foreign material
from the human proteins expressed from the hESC product. See Fink Jr., supra note 9, at
1662; see also Halme & Kessler, supra note 9, at 1730–31; see articles cited supra note 44.
64
Lau et al., supra note 63, at 591.
65
Id. at 592.
66
Barclay, supra note 20, at 884.
67
Bruce H. Dobkin et al., Cellular Transplants in China: Observational Study from the
Largest Human Experiment in Chronic Spinal Cord Injury, 20 NEUROREHABILITATION &
NEURAL REPAIR 5 (2006) (comparing available reports of patients who received preoperative
and postoperative assessments before and up to one year after receiving biological cell-based
implants in China).
68
Id.
69
Id. Meningitis is an inflammation of the membranes that cover the brain and spinal cord
and is primarily caused by either a viral or bacterial infection. U.S. Nat‘l Library of Med.,
Meningitis, MEDLINEPLUS, http://www.nlm.nih.gov/medlineplus/meningitis.html (last updated Mar. 25, 2011).
70
Ninette Amariglio et al., Donor-Derived Brain Tumor Following Neural Stem Cell
Transplantation in an Ataxia Telangiectasia Patient, 6 PLOS MED. 221(2009) (reporting on a
human brain tumor complicating neural stem cell therapy and advocating that further work is
urgently needed to assess the safety of certain stem cell-based therapies).
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offered in Russia to treat a rare neurological disorder called ataxia telangiectasia, which causes severe disability.71 However, instead of the treatment
improving the child‘s symptoms, he began to suffer from recurring headaches.72 When the child reported these new symptoms, researchers in Tel
Aviv discovered that the headaches were a result of abnormal growths that
developed in the child‘s brain and spinal cord from the stem cell-based injections.73
In another report, police in Hungary arrested four people in a raid
conducted on a suspected, rogue stem cell clinic.74 The clinic was charging
patients as much as $25,000 per treatment and injecting patients with illegally obtained embryonic and fetal stem cells.75 The cells used at the clinic
were derived without authorization or safety testing, posing serious risks to
the clinic‘s patients.76
While nothing is inherently wrong with stem cell tourism, the lack
of standards to prove safety and efficacy of hESC-based therapies is a valid
reason why such treatments are not available in Canada, the United States,
and many other nations.77 Additionally, individuals suffering from debilitating conditions in which there are no conventional medical treatments are
prime targets for clinics that market unregulated and potentially harmful
stem cell therapies.78 According to one stem cell tourist, ―[w]hen you‘ve
71
Id. at 223. ―Ataxia telangiectasia is a primary immunodeficiency disease which affects a
number of different organs in the body. Ataxia Telangiectasia: Fact Sheet, NAT‘L CANCER
INST., http://www.cancer.gov/cancertopics/factsheet/risk/ataxia (last updated Jan. 6, 2006).
An immunodeficiency disease is one that causes the immune system to break down, making
the body susceptible to diseases. Id. There is no cure for ataxia telangiectasia.‖ Id.
72
Amariglio et al., supra note 70, at 223.
73
Id.
74
Stem Cell Tourism on the Rise, CELL MED. (Aug. 13, 2009), http://www.cellmedicine.
com/tourism-caveat-emptor.asp (discussing the risks associated with stem cell tourism).
75
Id.
76
Id.
77
Lori P. Knowles, Stem Cell Hype and the Dangers of Stem Cell “Tourism”, STEM CELL
NETWORK/RÉSEAU DE CELLULES SOUCHES (2008), available at http://www.stemcellnetwork.
ca/uploads/File/whitepapers/Stem-Cell-Hype.pdf (white paper discussing the dangers of stem
cell tourism).
78
See David Cyranoski, Stem-cell Therapy Faces More Scrutiny in China but Regulations
Remain Unclear for Companies that Supply Treatments, 459 NATURE 146 (2009) (discussing
China‘s attempt to designate all forms of stem cell therapy as ―ethically problematic,‖ ―high
risk‖ or ―still in need of clinical verification‖); see also Patrick White, Stem Cell Therapy:
Cure or Hoax in China? GLOBE & MAIL (Aug. 23, 2007, 9:11 AM EDT),
http://www.theglobeandmail.com/life/article778149.ece (discussing individual patients that
are side-stepping Canadian domestic regulations and traveling to China in hopes of a cure);
Drew Griffin & David Fitzpatrick, U.S. Patients Try Stem Cell Therapies Abroad, CNN
(June 2, 2009, 10:37 PM EDT), http://www.cnn.com/2009/HEALTH/06/02/stem.cell.
therapy.
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been in a wheel chair [sic] for 14 years, do you think it really worries [me]
[sic] what treatment I receive?‖79
Another stem cell tourist discovered a website by Beike Biotechnology in China offering stem cell treatments to restore vision in blind
children.80 The family traveled to Hangzhou, China, with their blind, sevenmonth-old daughter and paid $23,000 for their infant to have infusions of
stem cells in her eyes.81 The doctors in China have told the parents that the
therapy is working in their daughter.82 Despite the Chinese doctors‘ assertions, Dr. Bruce Dobkin, Director of the Neurologic Rehabilitation and Research Program at the University of California, Los Angeles stated that, ―it
is extreme nonsense to think that cells can be incorporated into the complex
nervous system and do so much, when we cannot even get cells in mice and
rats to do very much.‖83 One Chinese scientist reasoned that, ―we think
money is mainly behind [the treatments offered by Beike Biotechnology],‖
and added his concern that Beike‘s advertised therapy will create a bad reputation for China‘s entire biotech industry.84
Seriously ill individuals are often drawn to the promise of research
or novel treatments because they believe it is a better alternative to standard
treatment or better than no treatment at all.85 When these individuals are in
search of a cure or treatment, it can lead to a decreased ability to properly
79

Interview by Jennifer Macey, reporter ABC, with Perry Cross, paraplegic stem cell
tourist (Oct. 17, 2008).
80
Louisa Lim, Stem-Cell Therapy in China Draws Foreign Patients, NPR (Mar. 18,
2008), http://www.npr.org/templates/story/story.php?storyId=88123868.
81
Id.
82
Id. Cf. Irana Klimanskaya et al., Derivation and Comparative Assessment of Retinal
Pigment Epithelium from Human Embryonic Stem Cells Using Transcriptomics, 6 CLONING
& STEM CELLS 217 (2004) (finding that with further research retinal pigment epithelium cells
derived from hESCs might have the potential to successfully restore vision in animal models
of age-related macular degeneration).
83
Lim, supra note 80; see also Klimanskaya et al., supra note 82.
84
Lim, supra note 80. According to one article, China‘s health ministry has ignored unauthorized stem cell therapies offered by hundreds of hospitals under its jurisdiction. Stem Cells
in China: Wild East or Scientific Feast?, ECONOMIST(Jan. 14, 2010), http://www.economist.
com/node/15268869. According to the article, Beike Biotechnology is infamous for its internet claims and marketing efforts in countries across the world. Id. Beike also openly claims
to supply stem cells to more than two dozen hospitals in China and one in Thailand for treating a myriad of conditions. Id. Despite Beike‘s claims that it treats over 6,000 patients using
novel stem cell therapies, the company has not published any papers in internationally recognized, peer-reviewed journals. Id.
85
CARL H. COLEMAN ET AL., THE ETHICS AND REGULATIONS OF RESEARCH WITH HUMAN
SUBJECTS 133 (2005). Medical vulnerability is identified by five categories of vulnerability:
(1) communicative, (2) institutional, (3) deferential, (4) medical, and (5) social. See J. Koffman et al., Vulnerability in Palliative Care Research: Findings from a Qualitative Study of
Black Caribbean and White British Patients with Advanced Cancer, 35 J. MED. ETHICS 440
(2009).
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weigh the risks and potential benefits associated with proposed treatments.86
This type of vulnerability increases the possibility that informed consent is
based on misunderstanding potential benefits or motivated solely by the
hope of finding a cure.87 This vulnerability also increases the risk that such
participants will be exploited, because either they have unreasonable expectations about the potential benefits or investigators mislead them about the
risks in relation to any potential benefits.88 Because of the lack of international regulation in this area, stem cell tourists who are harmed will find
themselves lacking a clear path for legal recourse or other assistance.
C.

International Regulation

1.

Human subjects research

It is the responsibility of the medical profession to insist that major
innovations, such as the application of hESCs in clinical practice, are first
incorporated into formal research projects.89 This is especially true given the
World Medical Association‘s (WMA) International Code of Medical Ethics
that states, ―[a physician shall] respect human life [and] act in the patient‘s
best interest when providing medical care.‖90
Notably, ―when a clinician departs in a significant way from standard or accepted practice, the innovation does not, in and of itself, constitute
research.‖91 Nonetheless, radically new procedures of this description must
be incorporated into formal research protocols at an early stage in order to
determine whether the procedures are safe and effective.92
86

COLEMAN ET AL., supra note 85.
Id.
88
Id. Federal regulations require Institutional Review Boards [IRBs] reviewing research
protocols to ensure that before approving any protocol, ―[r]isks to subjects are minimized‖
and ―[r]isks to subjects are reasonable in relation to anticipated benefits, if any.‖ 45 C.F.R. §
46.111(a)(1-2) (2011).
89
REPORT OF THE NAT‘L COMM‘N FOR THE PROTECTION OF HUMAN SUBJECTS OF
BIOMEDICAL AND BEHAVIORAL RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND
GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH, 44 Fed. Reg. 23192
(Apr. 18, 1979) (codified as 45 C.F.R. § 46) [hereinafter BELMONT REPORT].
90
WORLD MED. ASSOC., WMA INT‘L CODE OF MED. ETHICS (2006), available at
http://www.wma.net/en/30publications/10policies/c8/index.html. The World Medical Association [WMA] was founded in 1947 by twenty-seven countries and represents physicians
around the world. About the WMA, WORLD MED. ASSOC. (2011), http://www.wma.net/en/60
about/index.html.
91
BELMONT REPORT, supra note 89.
92
Id. (emphasis added). Regulatory approval of new therapies generally requires clear
evidence of efficacy and safety and researchers can only obtain this evidence by welldesigned and well-conducted randomized prospective clinical trials. See RICHARD CHIN &
BRUCE Y. LEE, PRINCIPLES AND PRACTICE OF CLINICAL TRIAL MEDICINE 7 (reprint 2008)
(1996).
87

File: DeRenzo 2

2011]

Created on: 4/2/2011 8:34:00 PM

Last Printed: 5/22/2011 7:42:00 PM

STEM CELL TOURISM

893

Further, clinics must not classify hESC-based therapy as an available ―treatment‖ until hESC-based therapy is generally recognized among
experts as a ―treatment.‖ Supporting this assertion, the U.S. Supreme Court
held that a drug is effective if there is general recognition among experts,
founded on substantial evidence, that the drug, in fact, produces the results
claimed for it under prescribed conditions.93 By parallel reasoning, experimental medical treatment must not be classified as an available treatment
unless there is general recognition among experts, founded on substantial
evidence, that the treatment, in fact, produces the results claimed under prescribed conditions. Thus, it is absolutely essential that a patient has the necessary information to make an informed decision when seeking information on whether to participate in novel ―treatments.‖
Having access to accurate and relevant information is essential to
make an informed decision regarding novel medical treatment. Even one of
the earliest known guidelines on human medical experimentation, promulgated in Germany in 1931, incorporated the concept of informed consent. 94
The guidelines, entitled, ―Regulations on New Therapy and Human Experimentation,‖ were issued by the German government in a Reich Circular on
February 28, 1931.95 The guidelines stated that ―[i]nnovative therapy may
be carried out only after the subject or his legal representative has unambiguously consented to the procedure in the light of relevant information provided in advance.‖96
Germany‘s guidelines proved futile, as it was the atrocious German
human experimentations during World War II that led to the Nuremberg
Doctors‘ Trial of 1946 and the resulting Nuremberg Code—the first international research guidelines.97 The very first line of the Nuremberg Code sets
forth the essential tenant of informed consent by declaring that ―[t]he voluntary consent of the human subject is absolutely essential.‖98

93

U.S. v. Rutherford, 442 U.S. 544 (1979) (holding that a drug is unsafe for the terminally
ill, as for anyone else, if its potential for inflicting death or physical injury is not offset by the
possibility of therapeutic benefit).
94
THE NAZI DOCTORS AND THE NUREMBERG CODE: HUMAN RIGHTS IN HUMAN
EXPERIMENTATION, supra note 25, at 129; see also Robert M. Sade, Publication of Unethical
Research Studies: The Importance of Informed Consent, 75 ANNALS OF THORACIC SURGERY
325 (2003).
95
THE NAZI DOCTORS AND THE NUREMBERG CODE: HUMAN RIGHTS IN HUMAN
EXPERIMENTATION, supra note 25, at 129.
96
Id. at 130–31(citing 11 Reichs-Gesundheitsblatt 174–75 (1931)); see also Sade, supra
note 94.
97
Sade, supra note 94, at 325.
98
2 TRIALS OF WAR CRIMINALS BEFORE THE NUERNBERG MILITARY TRIBUNALS UNDER
CONTROL COUNCIL LAW NO. 10 181–82 (U.S. Gov‘t Printing Office 1946-1949) [hereinafter
NUREMBERG CODE].

File: DeRenzo 2

894

Created on: 4/2/2011 8:34:00 PM

Last Printed: 5/22/2011 7:42:00 PM

CASE W. RES. J. INT‘L L.

[Vol. 43

Following the Nuremberg Code, the WMA approved the Declaration of Helsinki in 1964.99 The Declaration of Helsinki asserts that, ―every
medical research project involving human subjects should be preceded by
careful assessment of predictable risks and burdens in comparison with foreseeable benefits to the subject.‖100 Further, ―[t]he degree of risk taken
should never exceed that determined by the humanitarian importance of the
problem to be solved by the experiment.‖101
While the Nuremberg Code and the Declaration of Helsinki set international standards for treatment of human subjects when conducting
medical research, neither mandate the regulation of novel biomedical interventions postured as available treatments.102 Even the Convention of Oviedo
(Oviedo Convention), a prominent example of ethical rules related to the
application of biology, medicine, and research in human subject experimentation, does not regulate biomedical research disguised as a curative therapy.103
The Oviedo Convention, a legally binding instrument signed by
most of the European States, mandates that all ratifying States implement a
regulatory scheme to monitor biomedical research in relation to human subjects research.104 Echoing the informed consent requirements of the Nuremberg Code and Declaration of Helsinki, Article 5 of the Oviedo Convention
declares that, ―[a]n [experimental medical] intervention . . . may only be
carried out after the person concerned has given free and informed consent.‖105
Most importantly, Article 16 sets forth essential principles for the
ethical conduct of human subjects research.106 The Oviedo Convention
mandates that research on a person may only be undertaken if all of the following conditions are met: (i) [t]here is no alternative of comparable effectiveness to research on humans; (ii) [t]he risks which may be incurred by
that person are not disproportionate to the potential benefits of the research;
99

Sade, supra note 94.
World Med. Assoc., Declaration of Helsinki: Ethical Principles for Medical Research
Involving Human Subjects (June 1964), available at http://history.nih.gov/research/
downloads/helsinki.pdf (a statement of ethical principles that offers guidance to participants
in medical research involving human subjects) [hereinafter Declaration of Helsinki].
101
NUREMBERG CODE, supra note 98, at 182.
102
See generally Declaration of Helsinki, supra note 100; NUREMBERG CODE, supra note
98.
103
Convention for the Protection of Human Rights and Human Dignity of the Human
Being with Regard to the Application of Biology and Medicine: Convention on Human
Rights and Biomedicine, 1997, C.E.T.S. No. 164 [hereinafter Oviedo Convention].
104
Id.
105
Id. art. 5 (emphasis added).
106
Id. art. 16.
100
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(iii) [t]he research project has been approved by [a] competent body after
independent examination of its scientific merit . . .; (iv) [t]he persons undergoing research have been informed of their rights and the safeguards prescribed by law for their protection; and (v) [t]he necessary consent as provided for under Article 5 has been given expressly . . . and is documented.107
Because hESC-based therapies are not yet an acceptable curative
treatment or therapy, any proposed intervention that uses hESC-based products must take place within the constraints of a carefully planned clinical
trial.108 This will ensure the administration of hESCs falls under the provisions of the Nuremburg Code, Declaration of Helsinki, and Oviedo Convention (where applicable).109
2.

A call for international regulations—Past, present, & future

Many clinics offering dubious hESC-based treatments are located in
countries where regulations are less stringent regarding human subjects research.110 Stem cell scientists have expressed frustration with how the multijurisdictional nature of stem cell research makes it ―tremendously‖ difficult
to regulate.111 One analysis detailed the lack of international mechanisms
for accountability, transparency, and ethical oversight as the main reasons
for scientific regulatory system failures.112
Because of the regulatory difficulties, professional groups have issued guidelines in relation to providing hESC-based therapies. In particular,
the ISSCR issued guidelines entitled ―Clinical Translation of Stem Cells‖
that provide acceptable ways in which researchers may provide hESC-based
107

Id.
Regulatory approval of new therapies generally requires clear evidence of efficacy and
safety and researchers can only obtain this evidence by well-designed and well-conducted
randomized prospective clinical trials. See CHIN & LEE, supra note 92, at 7.
109
Notably, there are two additional, well-established guidelines that govern the use of
human subjects research throughout the world. They are: (1) THE COUNCIL FOR INT‘L
ORGS. OF MED. SCIENCES, INT‘L ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH
INVOLVING HUMAN SUBJECTS (2002) and (2) Universal Declaration on Bioethics and
Human Rights, UNESCO Gen. Conf. Res., 33rd Sess., 33 C/Resolution 36 (Oct. 19,
108

2005).
110

Kiatpongsan & Sipp, supra note 17. Examples of countries with less stringent regulations include: China, India, Russia, and Thailand. See id.
111
Monya Baker, Stick to the Guidelines and Fewer Get Hurt, NATURE REPORTS STEM
CELLS (Dec 11, 2008), http://www.nature.com/stemcells/2008/0812/081211/full/stemcells.
2008.157.html (discussing ISSCR‘s hope that its guidelines will prompt regulators and governments to close ―shady‖ clinics that offer unproven stem cell therapies); see also Guidelines for the Clinical Translation of Stem Cells, supra note 21.
112
See, e.g., Herbert Gottweis & Robert Triendl, South Korean Policy Failure and the
Hwang Debacle, 24 NATURE BIOTECH. 141 (2006).
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therapies.113 The ISSCR strongly condemns clinics that promote and administer unproven uses of stem cells, or their direct derivatives, to patients
outside of a clinical trial—particularly when patients are charged for those
services.114 Even so, the ISSCR concedes that it will not enforce the guidelines or evaluate individual clinics for compliance.115 Nonetheless, the
ISSCR is hopeful that the publication of its guidelines will push countries to
adopt and enforce harmonized regulatory standards.116
Another international professional society, the BIONET Expert
Group (BIONET), warns that legal, political, social, and cultural differences
between nations can lead to ―multiple standards and even to gaps [between]
governance regimes.‖117 BIONET has called for a joint advisory body to
monitor research practices internationally.118
Although setting common standards in the biomedical field can be
an arduous task, it is possible because international human rights law presupposes that some basic principles of human rights transcend cultural diversity.119 Additionally, international organizations such as the ISSCR and
BIONET provide a forum for discovering multinational standards in hESC
research.120
One example of collaboration in setting international scientific
standards is the Universal Declaration on the Human Genome and Human
Rights (Universal Declaration).121 The Universal Declaration publicized the
immense potential of therapeutic applications related to gene therapy, but
emphasized that any such research involving gene therapy should ―fully
respect human dignity, freedom[,] and human rights . . .‖122

113

Guidelines for the Clinical Translation of Stem Cells, supra note 21; see also Lindvall
& Hyun, supra note 20, at 1665.
114
Guidelines for the Clinical Translation of Stem Cells, supra note 21.
115
Stem-Cell Society Condemns Medical Tourism, 453 NATURE 969 (2008) (announcing
ISSCR‘s official condemnation towards clinicians offering unproven stem-cell treatments to
vulnerable patient populations).
116
Id.
117
Daniel Cressey, Ethics Scrutiny Needed for Chinese-European Projects, 461 NATURE
157 (2009).
118
Id.
119
Roberto Andorno, Biomedicine and International Human Rights Law: In Search of a
Global Consensus, 80 BULL. OF THE WORLD HEALTH ORG. 959 (2002) (discussing the global
challenges raised by biomedical advances).
120
Id.
121
Universal Declaration on the Human Genome and Human Rights, G.C. Res. 16, U.N.
ESCOR, 29th Sess., 26th plen. mtg. (Nov. 11, 1997).
122
Id.
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The United Nations responded similarly when citizens worldwide
learned that scientists had successfully cloned a sheep.123 Concern quickly
spread that scientists could apply the same technique to produce genetically
identical human beings.124 As a result, the French and German governments
petitioned the United Nations to approve a worldwide ban on human cloning.125 In response, on December 12, 2001, the U.N. General Assembly established the Ad Hoc Committee on an International Convention Against
the Reproductive Cloning of Human Beings.126 On March 8, 2005, the U.N.
General Assembly adopted a non-binding resolution calling for the ban of
all forms of human cloning contrary to human dignity.127
Professional society guidelines and U.N. declarations have formed a
directional point of origin to help determine the path forward in the regulation of hESC-based therapies. From here, a range of effective solutions
emerge—each helping to fulfill the promise of ever-advancing hESC-based
therapies. Specifically, this journey includes the analysis and application of:
(i) a binding U.N. Security Council Resolution to effectuate immediate action in the interest of national security and public health; (ii) a resolution
outside of the purview of biomedical regulation in which WHO could issue
a non-binding resolution; and (iii) model treaties and the codification of key
portions of the ISSCR guidelines into the form of a draft treaty.
III. HESC THERAPIES—A REGULATORY ROAD MAP TO HELP
GUIDE THE JOURNEY
Scientific advances are dependent on collaborative, international research—as science is not constrained by geographic boundaries. The international community must implement a standardized ethical and regulatory
framework to address the emerging and complex scientific and social challenges generated by hESC-based therapies. While there are various approaches the international community could take to regulate hESC thera123

Andorno, supra note 119. The term cloning is used to describe the process of making
duplicate biological material. Kathi E. Hanna, Cloning/Embryonic Stem Cells, NAT‘L HUM.
GENOME RES. INST.(Apr. 2006), http://www.genome.gov/10004765.
124
Andorno, supra note 119.
125
Id.
126
U.N. Ad Hoc Committee on an Int‘l Convention Against the Reproductive Cloning of
Human Beings, U.N., http://www.un.org/law/cloning/ (last updated May 15, 2005); see also
Erika Check, Call for Cloning Ban Splits UN, 416 NATURE 3 (2002) (discussing international
debate regarding the U.N.‘s proposed global ban on human cloning); Nigel Williams, UN
Stalls on Human Cloning, 14 CURRENT BIOLOGY R937 (articulating how the U.N.‘s attempt
to come up with a resolution on the issue of human cloning was postponed due to continued
debate amongst countries over a world-wide human cloning ban).
127
U.N. Declaration on Human Cloning, G.A. Res. 59/280, annex, U.N. Doc.
A/RES/59/280 (Mar. 23, 2005).
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pies, the establishment of a formal, international standard is the critical first
step to advance the regulation of hESCs. This section explores three different options available for the regulation of hESC-based therapies.
A.

Leveraging a Binding U.N. Security Council Resolution – Immediate Action to Protect National Security and the Public Health

1.

The binding resolution—Lessons from 9/11

Under the U.N. Charter, the Security Council has primary responsibility for maintaining international peace and security.128 Article 39 of the
Charter allows the Security Council broad discretion to assess whether
threats to peace exist, and Chapter VII provides for flexibility to decide on
appropriate responses.129 Article 25 of the Charter obligates member States
to comply with the binding Resolutions adopted by the Security Council
under its Chapter VII authority.130
On September 28, 2001, weeks after the horrific 9/11 attacks on
America, the Security Council adopted Resolution 1373—a ―wide-ranging,
comprehensive resolution with steps and strategies to combat international
terrorism.‖131 In effect, Resolution 1373 converted the International Convention for the Suppression of the Financing of Terrorism,132 which had not
yet been universally ratified, into instant international law, binding on all
192 Members of the United Nations. The Security Council then adopted
Resolution 1377 on November 28, 2001, reaffirming Resolution 1373.133
128

The U.N. Security Council has:
[P]rimary responsibility, under the Charter for the maintenance of international
peace and security . . . . [A] representative of each of its members must be present
at all times at United Nations Headquarters . . . . When a complaint concerning a
threat to peace is brought before [the Council], the Council‘s first action is usually
to recommend to the parties to try to reach agreement by peaceful means. In some
cases, the Council itself undertakes investigation and mediation. It may appoint
special representatives or request the Secretary-General to do so . . . . It may set
forth principles for a peaceful settlement.
U.N. Security Council: Background, U.N., http://www.un.org/Docs/sc/unsc_background.
html (last visited Mar. 26, 2011).
129
The U.N. Charter article 39 states ―[t]he Security Council shall determine the existence
of any threat to the peace, breach of the peace, or act of aggression and shall make recommendations, or decide what measures shall be taken in accordance with Articles 41 and 42, to
maintain or restore international peace and security.‖
130
U.N. Charter art. 25.
131
S.C. Res. 1373, U.N. Doc. S/RES/1373 (Sept. 28, 2001); see also Press Release, Security Council Adopts Wide-Ranging Anti-Terrorism Resolution; Calls for Suppressing Financing, Improving International Cooperation, U.N. Press Release SC/7158 (Sept. 28, 2001).
132

G.A. Res. 54/109, U.N. Doc. A/RES/54/109 (Feb. 25, 2000).

133

S.C. Res 1377, U.N. Doc. S/RES/1377 (Nov. 12, 2001).
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Resolution 1377 tasked the States with, among other action items, promoting best -practices in the areas covered by Resolution 1373, including the
preparation of model laws.134 Because the Security Council adopted Resolution 1377 under Chapter VII of the U.N. Charter, Resolution 1377 imposes
binding obligations (in contradistinction to voluntarily entering a treaty) on
Member States to address the global issue of threats to peace and security
represented by terrorism.135
According to one scholar, the Security Council, for the first time,
―[mandated] all [S]tates to take or to refrain from specified actions in a context not limited to disciplining a particular country.‖136 The U.N. Security
Council can only bind Member States if a determination is made by the Security Council, under Article 39, that a threat to the peace, breach of the
peace, or act of aggression exists.137
2.

Unregulated hESC-based therapies—A threat to peace?

Some experts warn that the major threat of hESC research is not the
often cited violation of ethical norms, but the possibility that stem cells will
be used to bring physical harm to the human race.138 While some may scoff
at the idea that this particular type of danger is possible, using biologics for
human harm is not a new concept.139 The deployment of biological agents is

134

Id.
Id.
136
Paul C. Szasz, The Security Council Starts Legislating, 96 AM. J. INT‘L L. 901 (2002)
(discussing how, for the first time, the United Nations Security Council used its Chapter VII
powers under the Charter with its resolution to counter the threat of terrorism).
137
See U.N. Charter, supra note 129 and accompanying text. The structure of the U.N.
Security Council consists of five permanent members with veto power (i.e., China, France,
Russia, the United Kingdom, and the United States) and ten elected non-permanent members
that serve for two-year terms. U.N. Charter arts. 23 & 27.
138
LEO FURCHT & WILLIAM HOFFMAN, THE STEM CELL DILEMMA: BEACONS OF HOPE OR
HARBINGERS OF DOOM? 195 (2008) (indicating that while stem cells offer the hope of creating or repairing tissues lost to age, disease, and injury—because of this very ability—they
hold the potential to incite an international biological arms race); see also Zach W. Hall,
Resource Review, Stem Cells and Leonardo’s Cave, 2 CELL STEM CELL 536 (discussing how
the authors of ―The Stem Cell Dilemma: Beacons of Hope or Harbingers of Doom?‖ are
rightly alarmed by the threats posed by the potential use of modern molecular technology to
produce biological weapons and see stem cells as a critical link in efforts to both evade and
produce such weapons).
139
See Amerithrax or Anthrax Investigation, FEDERAL BUREAU OF INVESTIGATION [F.B.I.],
http://www.fbi.gov/anthrax/amerithraxlinks.htm. ―Soon after the terrorist attacks of 9/11/01,
letters laced with anthrax began appearing in the U.S. mail. Five Americans were killed and
17 were sickened in what became the worst biological attacks in U.S. history.‖ Id.
135
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no longer a hypothetical scenario, but a potentially life-threatening reality.140
According to the NIH, the anthrax attacks, subsequent to 9/11, exposed vulnerabilities in the United States and abroad to unconventional
weapons employed by terrorists.141 More specifically, the use of anthrax
demonstrated that terrorists could use deadly pathogens and biologics to
threaten the health and safety of citizens around the world.142 Given the
enormity of the threat of a biological attack, NIH spent over $1.7 billion in
2009 towards biodefense research, with projections showing plans to spend
equivalent amounts in the following years.143
Of great concern with bioterrorism is that civilian populations vary
significantly in their susceptibility to exposure from harmful biological
agents—mainly due to differences in age (e.g., infants to the elderly) and
health (e.g., immunocompromised to healthy immune systems).144 Countries
around the world all face an uncertain, but real threat—the deliberate act of
introducing re-emerging and emerging communicable diseases into the civilian population.145 Additionally, authorities state that countries in the Middle East, South Asia, and Southeast Asia face the risk that transnational
140

Reschma Agarwal et al., Biological Warfare – An Emerging Threat, J. OF THE ASS‘NS OF
PHYSICIANS OF INDIA (2004).
141
The Role of NIH Biomedical Research in Responding to the Threats of Chemical, Biological, Radiological and Nuclear (CBRN) Terrorism: Hearing Before the H. Comm. on
Gov’t Reform, Subcomm. on Nat’l Sec., Emerging Threats, and Int’l Rel., 109th Cong. (2005)
(statement of Anthony S. Fauci, M.D., Director, Nat‘l Institute of Allergy and Infectious
Diseases, Nat‘l Institutes of Health, U.S. Dep‘t of Health and Hum. Services).
142
Id.
143
Research Portfolio Online Reporting Tools (RePORT), Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC), NIH, http://report.nih.gov/rcdc/
categories/default.aspx (last updated Feb. 14, 2011). NIH is the lead recipient of Federal
biodefense dollars. See Crystal Franco, Billions for Biodefense: Federal Agency Biodefense
Funding, FY2008-FY2009, 6 BIOSECURITY & BIOTERRORISM: BIODEFENSE STRATEGY,
PRACTICE, & SCI. 131, 138 (2008) (analyzing the budgets and allocations for biodefense at
the Departments of Health and Human Services, Homeland Security, Defense, Agriculture,
and State and the Environmental Protection Agency and the National Science Foundation).
144
Bioterrorism includes the use of ―living organisms, whatever their nature, or infective
material derived from them, which are used for hostile purposes and intended to cause disease or death in man, animals and plants, and which depend for their efforts on the ability to
multiply in the person, animal or plant attacked.‖ See, e.g., Nicholas J. Beeching et al., Biological Warfare and Bioterrorism, 324 BMJ 336, 336 (2002); Anthony S. Fauci, Bioterrorism: Defining a Research Agenda, 57 FOOD & DRUG L.J. 413 (2002) (analyzing the laws,
regulations, and policies affecting FDA-regulated products).
145
See Fauci, supra note 144, at 420. Pandemic influenza is an example of a re-emerging
disease. Id. In 1918. pandemic influenza killed an estimated twenty-five million people
worldwide, including 750,000 in the United States. Id. HIV/AIDS, an example of an emerging disease, has now killed more than twenty-two million people and infected forty million
others worldwide. Id.
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terrorist groups can acquire biologics easily, as they have poorly secured
biological laboratories and culture collections.146
One al-Qaeda training manual advocates for the use of biologics in
terrorist attacks.147 However, rudimentary lab equipment and limited access
to lethal strains hindered al-Qaeda‘s known bioweapons efforts.148 Despite
al-Qaeda‘s set-backs, some experts predict that a biological attack could
occur by the end of 2013.149 Even more, a news report from 2010 acknowledged the possibility that terrorist groups were selling fake pharmaceutics
on the black-market as a profit-making venture to fund terrorist activities for
the purpose of implementing a biological attack.150
The field of biotechnology is emerging and proliferating before the
full impact is understood and ―well before laws and policies are in place to
ensure their use for peaceful purposes.‖151 As one scholar noted, ―[e]very
major technology—metallurgy, explosives, internal combustion, aviation,
electronics, nuclear energy—has been intensively exploited, not only for
peaceful purpose, but also for hostile ones.‖152
One muggy Sunday in July 1939, physicists Leo Szilard and Eugene
Wigner paid a visit to Albert Einstein at Little Peconic Bay on Long Island, where he was spending the summer. They broke the news to Einstein
about the recent experimental work with neutrons. They suggested it
would be possible to use a neutron, discovered only seven years earlier, to
start a chain reaction in the uranium nucleus. His Response? ―I never
thought of that.‖ The man who launched a revolution in physics had not
imagined that his famous equation of 1905, E=mc2, might be used to release massive amounts of energy in a weapon of war. Six years later to the
day, July 16, 1945, the nuclear chain reaction that the world‘s greatest
scientific mind had never considered was initiated at the ―Trinity‖ atomic
bomb test site on a desert flat north-west of Alamogordo, New Mexico.153

Imagine a situation in which an unsuspecting stem cell tourist is injected with a communicable biological agent under the auspices of receiving
hESC-based therapy. This innocent individual, paying upwards of $65,000
146

BOB GRAHAM ET AL., THE REPORT OF THE COMMISSION ON THE PREVENTION OF WMD
PROLIFERATION AND TERRORISM xix (2008).
147
Joby Warrick, Officials Fear Toxic Ingredient in Botox Could Become Terrorist Tool,
WASH. POST (Jan. 25, 2010), http://www.washingtonpost.com/wp-dyn/content/article/2010/
01/24/AR2010012403013.html?hpid=topnews.
148
Id.
149
GRAHAM ET AL., supra note 146, at xv.
150
Warrick, supra note 147.
151
DANIEL M. GERSTEIN, BIOTERROR IN THE 21ST CENTURY 17 (2009).
152
Id. at 37 (citing NRC and the IOM, Globalization, Biosecurity, and the Future of the
Life Sciences 49.).
153
FURCHT & HOFFMAN, supra note 138, at 230.
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for putative therapy, may not only serve as a potential human vector to
transmit toxic biological agents, but may be unknowingly contributing to
the financing of terrorist activities.154 And, similar to worries articulated in
the 2010 news report, these unregulated clinics may be using funding from
stem cell tourists to advance other forms of bioweapons.155
While the probability of the above hypothetical situation is
unknown, so significant are the consequences that they cannot be left to
chance.156 Just as the world would not sit idly by as rouge scientists
assembled the components of a nuclear weapon, the United Nations must
act to ensure national security. As one atomic bomb historian prophetically
asserted days leading up to the Manhattan Project, ―[t]he bomb was latent in
nature as a genome is latent in flesh.‖157 Thus, unregulated hESC-based
therapies offered in rogue clinics around the world may fall under the
purview of the Security Council‘s Chapter VII authority. Furthermore,
Security Council Resolution 1377 provides the United Nations flexibility to
institute a standardized regulatory scheme for hESC-based therapy by
binding Member States to ―intensify their efforts to eliminate . . .
international terrorism.‖ 158
3.

Taking a proactive stance towards hESC regulation

While resolutions are typically non-binding legal instruments, the
flexibility to impose binding resolutions can be extremely powerful in
prompting individual States to act. For example, scholars assert that the
international community‘s agreement to refrain from directly or indirectly
154

See, e.g., Warrick, supra note 147 (purchasing pharmaceutics off the black-market may
fund terrorist activities).
155
See id.; Agarwal et al., supra note 140.
156
The factors which effect the issue of biological weapons include:
the dual use problem involving materials, equipment, and knowledge which has
both legitimate peaceful and (illegitimate) hostile applications; the biotechnology
revolution and related developments (e.g. synthetic biology); globalization and the
increase in trade; the inherent weaknesses in the existing law against the use and
development of biological weapons in the 1925 Geneva Protocol and the 1972 Biological Weapons Convention [―BWC‖]; . . . ; the threat posed by terrorists and nonstate actors and their increased interest in biological weapons; public and government fear of biological weapons use (particularly in Western states) that may have
an impact physically, economically, and psychologically well beyond any actual
‗success‘ rate; renewed interest in incapacitating and disabling chemical and biological substances; and a crisis of legitimacy related to the actions and policies to
counter the biological weapons threat.
JEZ LITTLEWOOD, MANAGING THE BIOLOGICAL WEAPONS PROBLEM: FROM THE INDIVIDUAL TO
THE INTERNATIONAL 4 (2006).
157
FURCHT & HOFFMAN, supra note 138, at 224.
158
S.C. Res. 1377, U.N. Doc. S/RES/1377 (Nov. 12, 2001).
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financing terrorist activities was successfully implemented through policies
in the United States and overseas.159 As a result, scholars declare that alQaeda suffered financially, inhibiting the ability to conduct terrorist activities.160
Yet, other scholars in the international community profess that the
United Nations resolution has had only a minimalistic impact on combating
the financing of terrorist activities.161 In particular, a report by a Security
Council monitoring group observed that al-Qaeda has sustained considerable financial resources despite international efforts to eliminate their funding.162
One explanation for this is the possibility that terrorist financing is
sustained by transferring funds through a corrupt organization that claims to
have charitable, social, or cultural goals.163 This may be further bolstered by
a Security Council Resolution that creates a humanitarian exception to
freezing financial assets if the assets are necessary to cover basic living expenses such as food, rent, mortgage, medicines, and medical treatment.164
Similar to al-Qaeda terrorists that operate independent from any one
foreign financial benefactor, raising their assets from legitimate and nondescript commercial entities, rogue stem cell clinics operate in various centers
around the world—each with sources of revenue difficult to track and control.165 Establishing an international regulatory framework is essential to
promoting security awareness in the life sciences community and mitigates
the ability of terrorists to employ biological technology for less than noble
purposes.166
As with any proposed solution, there will be difficulties in measuring its effectiveness. While there are conflicting reports about the level of
effectiveness anti-terrorist financing campaigns have had on the reduction in
terrorist activity, any positive effect, regardless of the size of the impact, is
159

U.S. TREASURY DEP‘T, CONTRIBUTION BY THE DEP‘T OF THE TREASURY TO THE
FINANCIAL WAR ON TERRORISM 5 (2002), available at http://www.treas.gov/press/releases/
reports/2002910184556291211.pdf; but see U.N. Security Council, Second Report of the
Monitoring Group Established Pursuant to Security Council Resolution 1363 (2001) and
Extended by Resolution 1390, 3, U.N. Doc. S/2002/1050 (Sept. 20, 2002).
160
U.S. TREASURY DEP‘T, supra note 159.
161
U.N. Security Council, supra note 159, at 3.
162
Id.; but see U.S. TREASURY DEP‘T, supra note 159, at 5.
163
JIMMY GURULÉ, UNFUNDING TERROR: THE LEGAL RESPONSE TO THE FINANCING OF
GLOBAL TERRORISM 104 (2008).
164
S.C. Res. 1452, ¶1, U.N. Doc. S/RES/1452 (2002) (emphasis added).
165
Fund-Raising Methods and Procedures for Int’l Terrorist Orgs. Before the Subcomm.on
Oversight and Investigations of the H. Comm. on Financial Services, 107th Cong. (2002)
(testimony of Steven Emerson, Exec. Dir. for the Investigative Project).
166
GERSTEIN, supra note 151, at 8, 139.
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meaningful. Therefore, leveraging the authority provided in Security Council Resolution 1377 is a critical first step to publicizing international consensus on hESC-based therapies.
However, if the Security Council is simply unable—due to lack of
actionable information—to address this issue as one that poses a threat to
national security, there are other necessary steps the United Nations should
take to address the risks associated with receiving unregulated hESCs.
B. Implementation of a Non-Binding UN Resolution – Looking For Short
Term Direction Outside of Biomedical Regulation
International consensus is critical to the success of mitigating the
chance that patients will suffer an adverse outcome from putative hESCbased therapies or that nations will experience public health threats from
untested biologics. While the lawmaking process is often accused of failing
to keep up with scientific advances, standardized ethical principles withstand the passage of time.167 Thus, the WHO must act to pass a non-binding
resolution, at a minimum, regarding the international community‘s standards in relation to hESC-based therapies.168 The WHO‘s constitution provides it the ability ―to propose conventions, agreements and regulations, and
make recommendations with respect to international health matters.‖169
Thus, the WHO can act to promote a non-binding resolution that condemns
clinics that offer unsafe hESC therapies.
While not topically analogous, the principles embodied in the U.N.
Resolution on Human Rights and Terrorism is a model resolution adaptable
by the WHO to the problem of clinics offering unsubstantiated hESC-based
therapies. Through the United Nation‘s Resolution on Human Rights and
Terrorism, the international community has spoken clearly, and without
ambiguity, expressing ―condemn[ation] [of] all acts, methods and practices

167

Andorno, supra note 119.
In 1948, the United Nations established the World Health Organization [WHO]. History of WHO, WHO, http://www.who.int/about/history/en/index.html. The WHO is the ―directing and coordinating authority for health within the [U.N.] [and is] responsible for providing leadership on global health matters, shaping the health research agenda, setting norms
and standards, articulating evidence-based policy options, providing technical support to
countries and monitoring[,] and assessing health trends.‖ About WHO, WHO,
http://www.who.int/about/en/. WHO acts ―as the directing and coordinating authority on
international health work.‖ Const. of the WHO, art. 2(a), 62 Stat. 2679, 14 U.N.T.S.
185. The World Health Assembly [WHA] is comprised of 193 U.N. Member States and
makes major policy decisions regarding the WHO‘s initiatives. Countries, WHO,
http://www.who.int/countries/en(listing WHO member states)(last visited Mar. 26,
168

2011).
169

Const. of the WHO, supra note 168, art. 2(k).
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of terrorism in all its forms and manifestations.‖170 The international community has further called upon States to ―refrain from financing, . . . providing training for, or otherwise encouraging terrorist activities.‖171
Both the statement of condemnation, and the call upon States to act,
is essential for a hESC-based therapies resolution. Following the United
Nation‘s lead in addressing terrorism, the WHO, acting in its capacity as the
specialized health agency of the United Nations, must issue a non-binding
resolution that (i) condemns clinics that promote or administer unproven
uses of stem cells to patients outside of a clinical trial and (ii) calls upon
States to close down clinics and sensor individuals that violate hESC-based
therapy guidelines.
While it is still too soon to know whether hESCs will offer the cures
millions of people hope for, what is certain is that the power of biotechnology crosses international boundaries more freely than ever.172 And, the key
to scientific progress is based on the ―unification rather than fragmentation
of knowledge.‖173 Thus, broader global cooperation among countries and
their biological scientists may be the world‘s best approach to promote
scientific progress.174
The impact of a resolution can help increase the safety, efficacy,
and transparency of hESC-based therapies and, in the process, reduce the
number of rouge stem cell clinics offering unregulated therapies.175 A resolution would also, in effect, increase knowledge and awareness and help
align stem cell tourists‘ expectations with the promise of hESC-based therapies.176 Thus, urging the regulation of hESC-based therapy can mean preventing susceptible patients in Hungary from paying thousands of dollars
for unregulated stem cell injections.177 Or, it could mean saving the child in
Israel from suffering abnormal growths on his brain and spine due to irresponsible and ineffective cell-based treatment.178
If countries adopt regulations based on the WHO‘s guidance, then
stem cell tourists can travel with additional confidence that they are pursuing hESC-based therapies that are regulated and, in the process, benefit
from international cooperation in science.
170

G.A. Res. 48/122, U.N. Doc. A/RES/48/122 (Dec. 20, 1993); see also G.A. Res. 49/185,
U.N. Doc. A/RES/49/185 (Dec. 23, 1994).
171
See G.A. Res. 51/210, ¶ 3(f)(5), U.N. Doc. A/RES/51/210 (Dec. 17, 1996).
172
GERSTEIN, supra note 151, at 192.
173
Id.
174
Id. at 194
175
See GREGORY D. KOBLENTZ, LIVING WEAPONS: BIOLOGICAL WARFARE AND
INTERNATIONAL SECURITY 8 (2009).
176
See GERSTEIN, supra note 151, at 143.
177
Stem Cell Tourism on the Rise, supra note 74.
178
Amariglio et al., supra note 70.
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Codifying the ISSCR Guidelines by Leveraging Principles from
Model Treaties

As previously discussed, hESC-based therapies have transcended
the national stage into a global forum in need of international regulation.179
And, if the U.N. Security Council does not leverage its powers under its
binding resolution, and the WHO does not propose a non-binding resolution, there are additional steps the United Nations can take to regulate
hESC-based therapies and mitigate the possibility of patients suffering adverse health outcomes from unregulated treatments.
1.

ISSCR guidelines

The Task Force for the Clinical Translation of Stem Cells, a multidisciplinary group of stem cell researchers, clinicians, ethicists, and regulatory officials from 13 countries, developed the ISSCR guidelines.180 The
ISSCR decided to take steps to prompt the international community to adopt
uniform regulations for hESC-based therapies.181 This was largely due to
the desire to mitigate the occurrence of adverse outcomes in vulnerable patient populations, persuaded by means of misleading advertising, to pursue
unproven stem cell-based therapies abroad.182
Because peer-reviewed scientific literature has not yet shown
hESCs to be safe for transplantation into humans, the ISSCR strongly condemns clinics that promote and administer unproven uses of stem cells to
patients outside of a clinical trial.183 More specifically, the ISSCR guidelines specify that ―all studies involving clinical applications of stem cells
must be subject to independent review, approval, and ongoing monitoring
by human subjects research oversight bodies.‖184 Further, the ISSCR reiterates the need for independent review and informed consent to maximize
respect for the voluntary nature of any subject‘s participation in clinical

179

HERBERT GOTTWEIS ET AL., THE GLOBAL POLITICS OF HUMAN EMBRYONIC STEM CELL
SCIENCE, 189–90 (2009) (investigating the interaction between national regulatory formation
and the global bio-politics of regenerative medicine and human embryonic stem cell
science).
180
Insoo Hyun et al., Commentary, New ISSCR Guidelines Underscore Major Principles
for Responsible Translational Stem Cell Research, 3 CELL STEM CELL 607, 609 (2008) (discussing core principles that should guide the responsible transition of basic stem cell research
into appropriate clinical applications).
181
Id.
182
Hyun et al., supra note 180, at 609.
183
Guidelines for the Clinical Translation of Stem Cells, supra note 21.
184
Id.
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trials.185 Fortunately, portions of the ISSCR guidelines are uniquely suited
for adoption into treaty language.
2.

Model treaties

The international community has come together to address many
human rights and public health issues through treaties. For instance, in
2005, the WHO successfully implemented International Health Regulations
to enhance the international community‘s ability to prevent and respond to
acute public health risks.186 The International Health Regulations are legally
binding on all 194 WHO Member States, including the United States.187
In June 1997, the WHO gained endorsements from the American
Public Health Association and the 10th World Conference on Tobacco and
Health to develop a treaty in response to the globalization of the tobacco
epidemic.188 On May 21, 2003, the World Health Assembly adopted the
WHO Framework Convention on Tobacco Control (FCTC), which entered
into force on February 27, 2005.189 In 2009, the FCTC published guidelines
on: (i) protecting public health policies with respect to tobacco control; (ii)
protecting individuals from exposure to tobacco smoke; (iii) establishing
packaging and labeling of tobacco products regulations; and (iv) banning
tobacco advertising, promotion, and sponsorship.190
Another treaty, the Convention on the Rights of Persons with Disabilities (CRPD), entered into force in May 2008 and serves as a successful
model for international action.191 To date, 147 countries have signed the
CRPD and 97 have ratified it.192 The CRPD treaty requires that States
―adopt all appropriate legislation‖ to ―ensure and promote the full realiza185

Id.
See What are the International Health Regulations?, WHO, http://www.who.int/
features/qa/39/en/index.html (last updated Apr. 10, 2008).
187
WHO, Revision of the International Health Regulations, WHO Doc. WHA58.3 (May
23, 2005).
188
See Maureen Bezuhly et al., International Health Law, 32 INT‘L L. 539, 550 (1998)
(discussing how WHO endeavored to build support for the development of a framework
convention on tobacco and how the U.N. focal point on tobacco, established and strengthened contacts with governments, nongovernmental organizations, and over thirty U.N.
organizations to garner international support).
189
WHO Framework Convention on Tobacco Control, 42 I.L.M. 518 (May 21, 2003).
190
WHO FRAMEWORK CONVENTION ON TOBACCO CONTROL, GUIDELINES FOR
IMPLEMENTATION: ARTICLE 5.3; ARTICLE 8; ARTICLE 11; ARTICLE 13 at 1 (2009) [hereinafter
FCTC GUIDELINES FOR IMPLEMENTATION].
191
Convention on the Rights of Persons with Disabilities art. 1, G.A. Res, 61/106, U.N.
Doc. A/RES/61/106 (Jan. 24, 2006).
192
U.N. Enable, U.N., http://www.un.org/disabilities/ (follow link to ―Signatories & Ratifications‖) (last visited Mar. 26, 2011).
186
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tion of all human rights‖ for people with disabilities.193 Additionally, States
must modify or abolish all existing ―laws, regulations, customs and practices that constitute discrimination‖ against people with disabilities.194 The
official United Nations interpretation of the CRPD requires States to include
explicit protections in their legal instruments, both in national laws and constitutions.195 And, according to the United Nations, the CRPD marks a ―paradigm shift‖ in international attitudes and approaches to persons with disabilities.196
An additional area of successful international action is demonstrated by the international regulation of child labor.197 In 1999, the International
Labour Organization (ILO), a tripartite U.N. agency that brings together
governments, employers, and workers to promote international regulations,
adopted the Worst Forms of Child Labour Convention as ILO Convention
No. 182.198 One hundred and seventy-three countries, including the United
States, have ratified the ILO Convention.199 The ILO Convention imparts
the need to ―reach out to the children at special risk‖ and prevent children
from engaging in the worst forms of child labor.200 The ILO Convention
further asserts that the ―best interests of the child shall be a primary consideration.‖201
On the broader subject of protecting individual interests, medical
treatment should not be classified as an available treatment unless there is
general recognition among experts, founded on substantial evidence, that
193

Convention on the Rights of Persons with Disabilities, supra note 191, art. 4, cl. 1.
Id.
195
ANDREW BYRNES ET AL., FROM EXCLUSION TO EQUALITY: HANDBOOK FOR
PARLIAMENTARIANS ON THE CONVENTION FOR THE RIGHTS OF PEOPLE WITH DISABILITIES AND
ITS OPTIONAL PROTOCOL III (2007).
196
Joint Statement of Commitment to the Convention on the Rights of Persons with Disabilities, United Nations Inter-Agency Support Group for the Convention on the Rights of
Persons with Disabilities (available online at www.un.org/disabilities/documents/iasg/soc.
pdf).
197
See Jonathan P. Hiatt & Deborah Greenfield, The Importance of Core Labor Rights in
World Development, 26 MICH. J. INT‘L L. 39, 41 (2004) (articulating how labor and trade
linkage provisions respect domestic labor law as well as core labor rights).
198
See Mission and Objectives, ILO, http://www.ilo.org/global/about-the-ilo/mission-andobjectives/lang--en/index.htm; see also ILOLEX Database of Int’l Labour Standards, Ratification by Country or by Convention, ILO, http://www.ilo.org/ilolex/english/newratframeE.
htm.
199
ILOLEX Database of Int’l Labour Standards, supra note 198.
200
ILO Convention (No. 182) Concerning the Prohibition and Immediate Action for the
Elimination of the Worst Forms of Child Labour, art. 7(2)(d), June 17, 1999, S. Treaty Doc.
No. 106-5 (1999), 2133 U.N.T.S. 151 [hereinafter Worst Forms of Child Labour Convention].
201
Id. art. 7(2)(d).
194
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the treatment, in fact, produces the results claimed under prescribed conditions.202 As such, hESC-based therapy must be treated as experimental and
conducted only in clinical trials until accepted as standard medical treatment.203 Once hESC-based therapies are categorized as research instead of
treatment, the informed consent requirements of the Nuremberg Code and
Declaration of Helsinki must apply. Additionally, Article 16 of the Oviedo
Convention must be codified in international regulations to harmonize standards in determining when it is permissible to conduct research on human
subjects.204 The principles from these treaties, taken with the ISSCR guidelines, form the basis to develop a comprehensive international regulatory
framework.
3.

Using the ISSCR guidelines and model treaties to create an international framework for regulating hESC-based therapy

To address vulnerable populations lured by deceptive and misleading advertising, the international community should adopt key principles
from the WHO FCTC to ban all misleading advertising promoting hESCbased therapies.205 Certainly, it is inevitable that spotlighting this issue internationally will bring about heightened public awareness.
Proposed hESC regulations must also address the lack of international regulations206 by requiring each ratifying State to take legislative action, or promote existing laws, to address clinics offering unregulated
hESC-based therapies.207
The draft hESC regulations (Draft Treaty), attached to this Note as
Appendix A, is based on, and adapted from, the ISSCR guidelines and the
previously discussed treaties.208 The Draft Treaty, if implemented, would
require ratifying States to: (i) declare all hESC-based therapies as experi202

Rutherford, supra note 93.
See generally INDIAN DEP‘T OF BIOTECHNOLOGY & INDIAN COUNCIL OF MED. RESEARCH,
GUIDELINES FOR STEM CELL RESEARCH AND THERAPY (2007). Despite India‘s guidelines,
there are still reports that unregulated hESC therapies are offered at clinics in India. See
Kiatpongsan & Sipp, supra note 17.
204
Oviedo Convention, supra note 103.
205
See WHO Framework Convention on Tobacco Control, supra note 189.
206
Kiatpongsan & Sipp, supra note 17.
207
See, e.g., WHO, Revision of the International Health Regulations, supra note 187;
WHO Framework Convention on Tobacco Control, supra note 189; Convention on the
Rights of Persons with Disabilities, supra note 191; and Worst Forms of Child Labour Convention, supra note 200.
208
See Guidelines for the Clinical Translation of Stem Cells, supra note 21; see also Oviedo Convention, supra note 103; WHO, Revision of the International Health Regulations,
supra note 187; WHO Framework Convention on Tobacco Control, supra note 189; Convention on the Rights of Persons with Disabilities, supra note 191; and Worst Forms of Child
Labour Convention, supra note 200.
203

File: DeRenzo 2

910

Created on: 4/2/2011 8:34:00 PM

Last Printed: 5/22/2011 7:42:00 PM

CASE W. RES. J. INT‘L L.

[Vol. 43

mental and allowable only in a clinical trial setting—until accepted as routine medical practice; (ii) promote public awareness regarding the medical
efficacy and safety of hESC-based therapies; (iii) ban all misleading advertising promoting hESC-based therapies; and (iv) take legislative action to
ensure criminal and civil liability for clinics offering unregulated hESCbased therapies.
And, while the attached Draft Treaty represents another key step
towards regulating hESC-based therapies, there are potential roadblocks and
objections to overcome.
4.

Roadblocks to achieving international regulation

Because 13 different countries already approve the ISSCR guidelines, garnering further consensus through United Nations action is quite
promising.209 At the same time, treaties can take a very long time to pass
and presumably longer yet to implement. For example, it took 21 years from
the inception of the CRPD to when it became international law.210 While
reaching consensus may be a time consuming process, the impact of global
consensus can be instrumental in changing State practices. For instance,
shortly after the passage of the Worst Forms of Child Labour Convention,
Indonesia became one of the first countries to take action to end the employment of 1,900 children working on dangerous fishing platforms. 211
Thus, criticizing the lawmaking process as slow is not sufficient reasoning
for abandoning a solution altogether.
Of greater concern than the speed of implementation is the fact that
the countries most likely to enter into a treaty are not likely to be the same
countries that allow clinics to exploit vulnerable patient populations. While
this is a relevant criticism, the very fact that international law condemns
such practices will raise public awareness and help mitigate instances of

209

Hyun et al., supra note 180, at 609.
Arthur O‘Reilly, A UN Convention on the Rights of Persons with Disabilities: the Next
Steps, 17 DISABILITY WORLD (2003), http://www.disabilityworld.org/01-03_03/news/
unconvention.shtml.
211
Press Release, Int‘l. Labour Org., ILO Worst Forms of Child Labour Convention Comes
into Force, (Nov. 17, 2000) (available online at http://www.ilo.org/global/About_the_ILO/
Media_and_public_information/Press_releases/lang--en/WCMS_007917/index.htm). The
ILO highlights several other examples of the impact of the Worst Forms of Child Labour
Convention. Id. Examples in the ILO‘s press release have included: (1) the establishment of
child labour training courses for all officials of the education department in Bangladesh; (2)
the development of a National Plan of Action for the eradication of the worst forms of child
labour in South Africa; (3) large-scale projects on commercial agriculture and fireworks
production; and (4) the development of large-scale projects on domestic service, child prostitution, mining and child soldiers. Id.
210
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unsuspecting stem cell tourists traveling abroad to receive putative therapies.
The international community can infer from the FCTC‘s findings
that exposure to tobacco advertisements increases the use of tobacco, and
analogously, exposure to hESC-based therapy advertisements increases the
occurrence of stem cell tourism.212 The FCTC chose to reduce the use of
tobacco by advocating for a comprehensive ban on tobacco advertising,
promotion, and sponsorship.213 Here, by increasing public awareness about
putative hESC-based therapies and decreasing the means of advertisement,
promotion, and sponsorship, the rate of stem cell tourism for these types of
therapies should decrease.
Also, it may be unfair to presume that all individuals and clinics offering putative hESC treatments have only financial or self-serving interests—some may truly believe that the treatments work. However, without
clinical efficacy, mere belief that a treatment is effective, without valid
proof, is not sufficient reasoning to expose patients to undue risk—
regardless of the size of economic or career impact. Further, this violates the
WMA‘s medical ethics guidelines to ―act in the patient‘s best interest when
providing medical care.‖214
Lastly, critics will argue that hESC-based therapy regulations will
limit the freedom of choice for global citizens in the selection of medical
care. However, this is not a sufficient reason to jeopardize the health and
financial well-being of vulnerable patient populations or expose the public
to unstable biological hazards. The ability and right of legislatures to protect
the health, safety, and welfare of the public has been upheld time and time
again.215
IV. CONCLUSION
Unregulated hESC-based therapies have transcended the national
stage into a global forum in need of international regulation. Several model
declarations and treaties serve as effective examples to develop and imple212

FCTC GUIDELINES FOR IMPLEMENTATION, supra note 190, at 49–59.
Id.
214
WMA INT‘L CODE OF MED. ETHICS, supra note 90.
215
See, e.g., Dent v. West Virginia, 129 U.S. 114 (1889) (examining the scope of the
states‘ discretion to regulate the practice of medical care); Lawton v. Steele, 152 U.S. 133
(1892) (outlining the power of the state to abate nuisances under the police powers); Austin
v. Tennessee, 179 U.S. 343 (1900) (upholding Tennessee‘s limits on the sale of cigarettes);
Compagnie Francaise de Navigation a Vapeur v. State Board of Health, 186 U.S. 380 (1902)
(upholding the state power to quarantine interstate commercial goods to protect the public);
Jacobson v. Massachusetts, 197 U.S. 11 (1905) (upholding the constitutionality of Massachusetts mandatory vaccination laws and declaring that persons are subjected to restraints
and burdens in order to secure the general comfort, health, and prosperity of the State).
213
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ment key portions of the ISSCR guidelines to protect human dignity and
public health and promote the obligation of a physician to do no harm.
Action by the U.N. Security Council is one immediate solution to
require States to mandate international regulation of hESC-based therapies.
Additionally, the attached Draft Treaty is a step in the right direction to protect all man-kind.216 All three solutions discussed can promote global best
practices in—and accelerate the promise of—translational stem cell therapies, while protecting the public health. If any of the solutions are implemented, they will, at a minimum, reduce the number of unregulated clinics
offering putative and potentially harmful hESC-based therapies.
The international community has come together to address many
human rights and public health issues in the past. Now is the time for the
United Nations to address clinics offering unsafe hESC-based therapies and
prompt the collaboration of the international community to advance science
while ensuring human dignity.
Just as science continues to quickly evolve, there are new regulatory
pathways to explore. Further research should apply lessons learned from
trade regulations and explore ways that international trade and commerce
laws can reward model stem cell clinics and penalize rogue clinics that violate international regulations. Specific areas to advance include: strengthening enforcement mechanisms, enhancing border control techniques,
establishing an international accreditation process, and imposing sanctions
on countries that detract from the promise of hESC-based therapies.
APPENDIX A
DRAFT LANGUAGE OF A MODEL HESC TREATY217
WHO Framework Convention on Human Embryonic Stem Cell-Based
Therapies
Preamble
The Parties to this Convention,
Determined to give priority to their right to protect public health,
216

See infra Appendix A.
Author of this Note adopted and tailored language from the following guidelines and
treaties: Guidelines for the Clinical Translation of Stem Cells, supra note 21; Oviedo Convention, supra note 103; WHO, Revision of the International Health Regulations, supra note
187; WHO Framework Convention on Tobacco Control, supra note 189; Convention on the
Rights of Persons with Disabilities, supra note 191; and Worst Forms of Child Labour Convention, supra note 200.
217
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Seriously concerned about the potential adverse impacts of human
embryonic stem cell (hESC) based treatments offered without peerreviewed safety and efficacy data from clinical trials,
Recognizing that cooperative action is necessary to protect patients
from receiving unproven hESC-based therapies to mitigate the potential of
suffering adverse health outcomes as a result,
Conscious of the valuable work being conducted by many States on
hESC transplantation regulation and commending the leadership of the
World Health Organization as well as the efforts of other organizations and
bodies of the United Nations and other international and regional intergovernmental organizations in developing measures on regulating the clinical
application of hESCs,
Recalling Article 12 of the International Covenant on Economic,
Social and Cultural Rights, adopted by the United Nations General Assembly on 16 December 1966, which states that it is the right of everyone to the
enjoyment of the highest attainable standard of physical and mental health,
Recalling also the preamble to the Constitution of the World Health
Organization, which states that the enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition,
Determined to promote clinical translation of hESC-based therapies
based on current and relevant scientific, technical and economic considerations,
Conscious that the misuse of biology and medicine may lead to acts
endangering human dignity,
Stressing the need for international co-operation so that all humanity may enjoy the benefits of biology and medicine,
Resolving to take measures as necessary to safeguard human dignity
and the fundamental rights and freedoms of the individual with regard to the
application of biology and medicine,
Have agreed, as follows:
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Article 1
Allowing hESC-based Therapies in Approved Clinical Trials
The Parties undertake to develop and promote national research and
to coordinate research programs at the regional and international levels in
the field of hESC clinical applications. Each party shall only conduct hESC
research on human subjects when:
(a) there is no alternative of comparable effectiveness to research
on humans;
(b) the risks which may be incurred by that person are not dispro portionate
to the potential benefits of the research;
(c) the research project has been approved by a competent institutional
review board or other regulatory body after independent examination
of its scientific merit, including assessment of the importance of the
aim of the research, and multidisciplinary review of its ethical ability;
(d) the persons undergoing research have been informed of their rights and
the safeguards prescribed by law for their protection; and
(e) the persons undergoing research have expressly given free and informed consent that is then documented.
Article 2
Education, Communication, and Public Awareness
Each party shall promote and strengthen public awareness of hESCbased therapies, using all communication tools, as appropriate. Towards this
end, each Party shall adopt and implement effective legislative, executive,
administrative or other measures to promote:
(a) broad access to effective and comprehensive educational and public
awareness programs on the health risks of receiving unregulated hESCbased therapies;
(b) public access, in accordance with national law, to a wide range of information on hESC-based therapies; and
(c) awareness and participation of public and private agencies and nongovernmental organizations in developing and implementing intersectoral programs and strategies for hESC-based therapy regulation.
Article 3
Advertising, Promotion, and Sponsorship of hESC-based Therapies
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1. Parties recognize that a comprehensive ban on advertising,
promoting, and sponsorship of unregulated hESC-based therapies would
reduce the availability of such unregulated hESC-based therapies to vulnerable patient populations.
2. Each Party shall, in accordance with its constitution or constitutional principles, undertake a comprehensive ban on all unregulated hESCbased therapy advertising, promotion, and sponsorship. This shall include a
comprehensive ban on cross-border advertising, promotion, and sponsorship
origination from its territory. In this respect, within the period of five years
after entry into force of this Convention for that Party, each Party shall undertake appropriate legislative, executive, administrative or other measure
to ban such advertisements, promotions, and sponsorships.
Article 4
Protection from Exposure to Unregulated hESC-based Therapies
1. Parties recognize that scientific evidence has not established the
safety and efficacy of hESC-based therapies as standard medical treatment
and until such data is available, any proposed hESC-based therapy must be
conducted in a clinical trial setting that has been approved by an institutional review board.
2. Each Party shall adopt and implement in areas of existing national jurisdiction as determined by national law, and actively promote at
other jurisdictional levels, the adoption and implementation of effective
legislative, executive, administrative and other measures, providing for protection from unregulated hESC-based therapies.
3. For the purpose of this Convention, the parties shall take legislative action or promote existing laws to deal with criminal and civil liability, including allowing compensation for individuals injured by unregulated
hESC-based therapies where appropriate.
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APPENDIX B218

(© 2006 Terese Winslow)

218

U.S. DEP‘T OF HEALTH AND HUMAN SERVICES, REGENERATIVE MEDICINE, supra note 6,
at 2 fig. 1.2.

File: DeRenzo 2

2011]

Created on: 4/2/2011 8:34:00 PM

Last Printed: 5/22/2011 7:42:00 PM

STEM CELL TOURISM

917

APPENDIX C219

(© 2006 Terese Winslow)

219

U.S. DEP‘T OF HEALTH AND HUMAN SERVICES, REGENERATIVE MEDICINE, supra note 6,
at 3 fig. 1.3.
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APPENDIX D220

(© 2006 Terese Winslow)
220

U.S. DEP‘T OF HEALTH AND HUMAN SERVICES, REGENERATIVE MEDICINE, supra note 6,
at 1 fig. 1.1.

